SCHEMBL7109635

SCHEMBL7109635

Fc1ccc(-c2csc(Nc3cc(Cl)cc(Cl)c3)n2)cc1F

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 8/20 0.74
CYP1A1 P04798 7/20 0.61
CYP1A2 P05177 7/20 0.61
CYP1B1 Q16678 7/20 0.61
VCP P55072 4/20 0.52
MEN1 O00255 1/20 0.52
DEGS1 O15121 1/20 0.52
MAP4K4 O95819 1/20 0.52
CYP3A4 P08684 1/20 0.52
AMY1A P0DUB6 1/20 0.52
MAPT P10636 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
MAPK1 P28482 1/20 0.52
MAPKAPK2 P49137 1/20 0.52
KMT2A Q03164 1/20 0.52
PIM3 Q86V86 1/20 0.52
MINK1 Q8N4C8 1/20 0.52
SPHK2 Q9NRA0 1/20 0.52
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7115739 0.87 ALOX5 (0.81) ALOX5CYP1A1CYP1A2CYP1B1VCP
SCHEMBL7113187 0.85 ALOX5 (0.65) ALOX5VCPMEN1DEGS1MAP4K4
SCHEMBL7116150 0.82 ALOX5 (0.52) ALOX5VCPMEN1DEGS1MAP4K4
SCHEMBL12298054 0.82 CYP1A1 (0.82) ALOX5CYP1A1CYP1A2CYP1B1VCP
SCHEMBL28701564 0.82 CYP1B1 (0.77) ALOX5CYP1A1CYP1A2CYP1B1MAPT
SCHEMBL7246864 0.81 ALOX5 (0.79) ALOX5CYP1A1CYP1A2CYP1B1VCP
SCHEMBL12157973 0.80 ALOX5 (0.73) ALOX5VCPMEN1AMY1AMAPT
SCHEMBL28117072 0.80 MEN1 (0.64) ALOX5CYP1A1CYP1A2CYP1B1MEN1
SCHEMBL12157914 0.79 MPL (0.56) ALOX5VCPMEN1AMY1AMAPT
SCHEMBL7153995 0.79 ALOX5 (0.62) ALOX5CYP1A1CYP1A2CYP1B1VCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220380-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-11-27 US claimed
US-6586453-B2 Useful in prophylaxis or treatment of thrombosis, angina, pectoris, cerebral infarction, myocardial/pulmonary infarction, intra-atrial thrombus in atrial fibrillation, diabetic complications, restenosis, and stroke 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-07-01 US claimed
US-20010044545-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-11-22 US claimed
US-20030220380-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-11-27 US disclosed
WO-2001074793-A2 SUBSTITUTED THIAZOLES AND THE USE THEREOF AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044545-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 ALOX5 2040/4885CYP1A1 669/4885CYP1A2 1458/4885
US-20030220380-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 ALOX5 2040/4885CYP1A1 669/4885CYP1A2 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.